Cite
MLA Citation
Thomas Dörner et al.. “Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.” Annals of the rheumatic diseases, vol. 78, no. 5, 2019, pp. 641–647. http://access.bl.uk/ark:/81055/vdc_100175495393.0x000063